Skip to main content
AI Drug DiscoveryIsomorphic Labs· 5 min read· in Business

Isomorphic Labs Raises $5 Billion Series C to Advance AI Drug Design Engine

The Alphabet spinoff secured one of the largest private biotechnology investments in history to push its first AI-designed therapeutic candidates into clinical trials. Greenoaks and Sequoia Capital co-led the oversubscribed round, pushing the startup's total funding to $7.7 billion.

By Andre Figueira

Share this story

Listen

Isomorphic Labs, the London-based artificial intelligence drug discovery company founded by Sir Demis Hassabis, has secured a massive $5 billion Series C funding round. The investment accelerates the Alphabet spinoff's mission to design novel medicines using advanced simulation models.[1][2]

Greenoaks and Sequoia Capital co-led the oversubscribed financing, marking one of the largest private biotechnology raises in history. The round arrives just six months after Isomorphic closed a $2.1 billion Series B in May 2026, highlighting intense investor appetite for AI-driven healthcare.[1][2]

The latest capital injection pushes the startup's total external funding to $7.7 billion since its first $600 million round in March 2025. Alphabet made a significant follow-on investment, joining new backer Andreessen Horowitz and a coalition of returning sovereign wealth and venture funds.[3]

Isomorphic will deploy the $5 billion to scale its proprietary drug design engine, known as IsoDDE, and build a global bioengineering infrastructure. The immediate priority is advancing the company's first internally developed therapeutic candidates toward human clinical trials.[1][3]

Scaling the IsoDDE Platform

The IsoDDE platform unifies foundational simulation models designed to operate natively across multiple therapeutic areas and drug modalities. By exploring vast chemical spaces digitally, the system allows researchers to engineer molecules with optimal drug-like properties before synthesizing them in a physical laboratory.[1][3]

Isomorphic President Max Jaderberg emphasized the platform's practical impact on pharmaceutical bottlenecks. "Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades," Jaderberg stated.[1]

Isomorphic Labs has secured $7.7 billion in total external funding across three major rounds.

The technology builds upon the Nobel Prize-winning AlphaFold system developed by Google DeepMind, which Hassabis also chairs. The platform uses proprietary agents that navigate and reason through complex biology, aiming to predict how a potential drug molecule will interact with its intended target.[1][3]

Sequoia Capital partner Konstantine Buhler noted that Isomorphic has discovered crucial scaling laws for its biological models. This dynamic means the platform's predictive accuracy and generation speed continue to improve linearly as more computing power and training data are applied.[2]

Moving Toward Clinical Trials

The fresh capital will fund the extensive translational and clinical development infrastructure required to test these AI-designed molecules in human patients. Isomorphic is currently advancing a wholly owned internal pipeline focused primarily on complex oncology and immunology targets.[1][3]

The company has reported positive preclinical results across multiple internal programs, setting the stage for regulatory submissions. Hassabis indicated that Isomorphic expects to drive its first therapeutic programs into clinical trials by the end of 2026, with broader pipeline announcements slated for 2027.[2]

Beyond its proprietary pipeline, Isomorphic is generating revenue and validating its models through high-profile pharmaceutical partnerships. The company is currently collaborating with industry giants Novartis, Eli Lilly, and Johnson & Johnson to accelerate their respective drug discovery pipelines.[2][3]

The Eli Lilly collaboration focuses specifically on small-molecule therapeutics against undisclosed targets, while the multi-target Johnson & Johnson partnership spans both small molecules and biologics. Novartis began its work with Isomorphic in January 2024, expanding the agreement in February 2025 to include additional research programs.[3]

The IsoDDE platform explores vast chemical spaces digitally to engineer molecules with optimal drug-like properties.

These partnerships provide Isomorphic with crucial validation and access to proprietary, high-quality biological data. By training its models on the vast historical datasets maintained by these pharmaceutical giants, the startup can refine its algorithms far faster than it could using public data alone.[2][3]

Hassabis outlined an ambitious operational scale for the newly funded infrastructure. "What we're trying to build is a platform to do hundreds of drugs a year," Hassabis explained, noting that the company plans to expand beyond small molecules into large-molecule biologics.[2]

The Venture Capital AI Rush

The Series C round drew heavy participation from Isomorphic's existing capitalization table, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The sheer size of the round reflects a broader venture capital frenzy surrounding generative AI applications.[1][2]

While Isomorphic did not officially disclose its updated valuation, Bloomberg reported that the round values the company at approximately $50 billion. The rapid fundraising pace provides Isomorphic with an unprecedented war chest to secure massive computing pipelines and attract top-tier machine learning talent.[2]

The investment also underscores Alphabet's strategic commitment to dominating the intersection of artificial intelligence and biology. By maintaining a significant stake in Isomorphic, Alphabet positions itself to capture the massive financial upside of AI-generated therapeutics while insulating the research from DeepMind's core consumer focus.[1][2]

Addressing industry concerns about computing bottlenecks following recent executive shakeups at chipmaker Nvidia, Hassabis reassured investors about Isomorphic's hardware access. "We've got very secure compute pipelines," Hassabis told Bloomberg, noting that Google designs its own custom artificial intelligence chips.[2]

Illustration: The company's biological simulation models require massive computing pipelines to process complex molecular data.

The Road Ahead for AI Medicine

Despite the historic capital influx and promising preclinical data, the ultimate acid test for Isomorphic Labs remains the clinical efficacy of its candidates. No regulatory agency has yet approved a medicine designed entirely from scratch by artificial intelligence models.[2][3]

Traditional drug discovery takes an average of ten years and costs upwards of $2 billion per approved medicine, with a 90 percent failure rate in clinical trials. Isomorphic aims to drastically reduce both the timeline and the attrition rate by predicting toxicity and efficacy computationally.[1][3]

The company is actively building a partner ecosystem to advance the fundamental understanding of mechanistic disease biology. By integrating proprietary AI with vast biological datasets, Isomorphic hopes to target diseases that have historically been considered "undruggable" by conventional pharmaceutical methods.[1][3]

Regulatory bodies, including the FDA and the EMA, are simultaneously preparing for a wave of AI-generated investigational new drug applications. The agencies are developing new frameworks to evaluate the safety and efficacy of molecules that were engineered through algorithmic simulation rather than traditional high-throughput screening.[2]

The success or failure of Isomorphic's first clinical candidates will likely serve as a bellwether for the entire AI drug discovery sector. If the IsoDDE-designed molecules prove safe and effective in humans, it would validate a fundamental shift in how the pharmaceutical industry operates.[2][3]

The success or failure of Isomorphic's first clinical candidates will likely serve as a bellwether for the entire AI drug discovery sector.

For now, the $5 billion Series C ensures that Isomorphic Labs has the resources to push its computational theories into physical reality. The coming clinical trials will determine whether AI can truly fulfill its promise of addressing the global burden of complex diseases.[1][3]

Key points

  • Isomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital to advance its AI drug design engine.
  • The Alphabet spinoff has now secured $7.7 billion in total funding, following a $2.1 billion Series B round just six months prior.
  • The capital will fund the clinical development infrastructure needed to push the company's first internally developed oncology and immunology candidates into human trials.
  • Isomorphic is also expanding its pharmaceutical partnerships, collaborating with Novartis, Eli Lilly, and Johnson & Johnson to accelerate their respective drug pipelines.

Unanswered questions

  • The exact valuation of Isomorphic Labs following the Series C round, though secondary reports suggest approximately $50 billion.
  • Which specific disease targets the company's internal oncology and immunology programs are currently addressing.
  • How the AI-designed molecules will actually perform in human clinical trials, as no fully AI-generated drug has yet received regulatory approval.
  • Due to thin primary coverage from major financial outlets today, the specific terms and board seat allocations associated with the new venture capital investments remain undisclosed.

How we got here

  1. 2021

    Isomorphic Labs is founded as an Alphabet spinoff to build upon Google DeepMind's AlphaFold research.

  2. January 2024

    Novartis signs an initial collaboration agreement to develop small-molecule therapeutics against three challenging targets.

  3. March 2025

    Isomorphic raises its first external funding round of $600 million, led by Thrive Capital.

  4. May 2026

    The company secures a $2.1 billion Series B financing round to scale its operations.

  5. November 2026

    Greenoaks and Sequoia Capital co-lead a $5 billion Series C to push the first candidates toward clinical trials.

AI Biotech Optimists 50%Cautious Industry Observers 50%
AI Biotech Optimists
Argue that computational simulation will fundamentally solve the pharmaceutical industry's high attrition rate by predicting toxicity early.
Cautious Industry Observers
Maintain that computational predictions must still survive the unpredictable realities of human clinical trials before the technology is proven.

Perspectives this story doesn't cover

  • Regulatory agencies evaluating AI-generated drug applications
  • Patient advocacy groups awaiting new treatments

Sources

Source coverage

3 outlets

2 viewpoints surfaced

AI Biotech Optimists 50%Cautious Industry Observers 50%
  1. [1]Tech.euAI Biotech Optimists

    Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs

    Read on Tech.eu →
  2. [2]The Next WebCautious Industry Observers

    Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design

    Read on The Next Web →
  3. [3]Unite.AIAI Biotech Optimists

    Isomorphic Labs Raises $5B Series C to Advance AI Drug Design

    Read on Unite.AI →
Listen

Comments

Stay informed

Every angle. Every day.

Get Business stories with full source coverage and perspective breakdowns, free every day.